An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment

Trial Profile

An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Ixazomib (Primary) ; Cyclophosphamide; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 25 Jun 2017 Results (n=70;data cut off: 29 June 2016) assessing efficacy and safety, presented at the 22nd Congress of the European Haematology Association.
    • 06 Dec 2016 Results (n=78) assessing efficacy and safety of Ixazomib in patients with relapsed/refractory multiple myeloma, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 08 Dec 2015 Preliminary analysis (n=70) with data cut-off of July 1, 2015 were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top